Mounjaro constipation symptom guide

Mounjaro constipation: current rates and warning signs

Review constipation during Mounjaro care using the current Eli Lilly label, including adult trial rates, bowel-obstruction warning signs, glucose and medication context, presentation checks, and compounded-product distinctions.

Educational guideUpdated August 13, 2026

A product-first constipation check during Mounjaro care

Confirm the product is authentic Eli Lilly Mounjaro and identify the exact single-dose pen, single-dose vial, multi-dose vial, or KwikPen presentation.

Describe the change from baseline: bowel-movement frequency, stool hardness, straining, incomplete emptying, bloating, pain, and whether stool and gas still pass.

Record onset, duration, severity, food and fluid intake, urine output, glucose context, and timing relative to treatment, a clinician-directed change, refill, illness, travel, or another medicine.

Contact the prescriber before changing Mounjaro or adding a laxative, fiber product, magnesium product, enema, suppository, or supplement.

Use prompt in-person care for severe abdominal, obstruction-like, dehydration, bleeding, neurologic, or other emergency warning signs.

Direct answer

Constipation is a common Mounjaro adverse reaction. In pooled placebo-controlled trials in adults with type 2 diabetes, constipation occurred in 6%, 6%, and 7% of participants across the three listed Mounjaro groups versus 1% with placebo. Those adult trial rates do not predict one person’s cause, severity, or duration, and they do not establish a rate for pediatric use or compounded tirzepatide. Contact the prescriber for new, persistent, worsening, painful, or function-limiting constipation. Severe or persistent abdominal pain, repeated vomiting, marked abdominal swelling, inability to pass stool or gas, blood or black stool, fainting, confusion, or inability to keep fluids down needs prompt in-person assessment.

Current label answer

Adult Mounjaro trials report constipation by studied group

The current Eli Lilly Mounjaro prescribing information, effective April 22, 2026, lists constipation among the most common adverse reactions. In pooled placebo-controlled trials in adults with type 2 diabetes, constipation was reported in 1% of placebo participants and 6%, 6%, and 7% across the three listed Mounjaro groups. These percentages belong to the adult trial table. They do not predict an individual result, establish one expected duration, or provide a pediatric incidence rate.

Keep each percentage tied to the adult Mounjaro placebo-controlled trials rather than presenting one number as a universal tirzepatide rate.
Do not transfer Zepbound weight-reduction trial percentages to Mounjaro; the products have different labeled uses, populations, and adverse-reaction tables.
A label association does not prove Mounjaro caused every bowel change, so the exact symptom pattern, timing, intake, other medicines, and medical history still matter.

Symptom pattern and urgency

Routine bowel changes and obstruction-like symptoms need different pathways

Constipation can mean fewer bowel movements, harder stools, straining, incomplete emptying, or a meaningful change from a person’s usual pattern. Current Mounjaro labeling also lists postmarketing reports of ileus, intestinal obstruction, and severe constipation including fecal impaction. Voluntary reports from a population of uncertain size cannot provide a reliable frequency or prove causality, but they support taking severe, progressive, or obstruction-like symptoms seriously.

Record the last bowel movement, stool consistency, ability to pass gas, abdominal swelling, pain location and severity, nausea or vomiting, fever, bleeding, intake, and urine output.
Contact the prescriber for a persistent or worsening change, painful bowel movements, marked straining, symptoms after a refill or clinician-directed change, or constipation that affects eating, drinking, sleep, normal activity, or diabetes care.
Seek prompt in-person assessment for severe or persistent abdominal pain, repeated vomiting, marked swelling or a rigid abdomen, inability to pass stool or gas, blood or black stool, fainting, confusion, severe weakness, markedly reduced urination, or inability to keep fluids down.

Glucose, medicines, and medical history

Other causes and diabetes medicines can change the assessment

A bowel-pattern change may overlap with reduced food or fluid intake, travel, illness, pregnancy, a prior gastrointestinal condition, or another medicine. Opioid pain medicines, iron, some antacids, anticholinergic medicines, some antidepressants, antihistamines, and other products can contribute to constipation. Mounjaro can also increase low-blood-sugar risk when used with insulin or an insulin secretagogue such as a sulfonylurea. Dizziness, weakness, sweating, or confusion therefore needs glucose context as well as bowel and hydration review.

Share prior constipation, bowel obstruction or surgery, hernia, severe gastroparesis, kidney or heart disease, pregnancy possibility, recent illness, and meaningful changes in food, fluid, activity, or weight.
List insulin, sulfonylureas, opioid medicines, iron, antacids, antihistamines, antidepressants, anticholinergic medicines, laxatives, fiber, magnesium, vitamins, supplements, alcohol, and cannabis products.
Do not combine laxatives, use repeated enemas, start a “detox,” or follow a forum clean-out plan without individualized clinician or pharmacist guidance.

Product, population, and presentation

Current Mounjaro identity is broader than an adult-only pen description

Current Mounjaro labeling covers adults and pediatric patients age 10 and older with type 2 diabetes and lists pre-filled single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. Peptide12 provides adult care; that service boundary does not change the FDA label. The constipation percentages above come from adult placebo-controlled trials and should remain identified as adult evidence. Zepbound also contains tirzepatide but has different indications and label tables.

Preserve the product name, indication, presentation, prescription label, manufacturer, refill or lot details, storage history, and a photo of the current package.
Use presentation-specific manufacturer training; do not transfer instructions among pens, vials, KwikPens, Zepbound, or a compounded vial.
Do not skip, repeat, stop, restart, split, increase, decrease, or otherwise change Mounjaro based on a generic constipation guide.

Compounded-product boundary

Mounjaro trial rates do not establish a compounded-tirzepatide constipation rate

Mounjaro is an FDA-approved finished tirzepatide product with manufacturer-specific ingredients, presentations, instructions, and evidence. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro or an FDA-approved generic Mounjaro finished product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. Constipation after a refill or product change should prompt verification of the exact product and pharmacy rather than an assumption that every pen or vial is interchangeable.

Bring the compounded prescription label, concentration, dispensing pharmacy, refill details, storage history, beyond-use date, and a photo of the container to the responsible clinician.
Branded Mounjaro trial rates do not establish the incidence, quality, sterility, or clinical equivalence of a compounded preparation.
Avoid research-use products, unlabeled vials, counterfeit pens, copied syringe or bowel-cleanout charts, and sellers that provide tirzepatide without prescription-first clinician review.

Patient safety checklist

Questions to ask about constipation during Mounjaro care

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the product authentic Eli Lilly Mounjaro, and is the exact presentation a single-dose pen, single-dose vial, multi-dose vial, or KwikPen?

✓

What changed from my usual bowel pattern, when did it start, when was my last bowel movement, and can I still pass gas?

✓

Do I have severe or persistent pain, marked abdominal swelling, repeated vomiting, fever, blood or black stool, dizziness, fainting, confusion, reduced urination, or inability to keep fluids down?

✓

Did symptoms follow treatment, a clinician-directed change, a refill, illness, travel, reduced intake, another medicine, or a new supplement?

✓

Could insulin, a sulfonylurea, opioids, iron, antacids, antihistamines, antidepressants, anticholinergic medicines, laxatives, fiber, magnesium, or another product change the assessment?

✓

Do prior bowel obstruction or surgery, severe gastroparesis, hernia, kidney or heart disease, pregnancy possibility, or another condition change the safest plan?

✓

Which individualized food, fluid, activity, or bowel-product steps are appropriate, and when should I report that they are not working?

✓

Who should I contact before the next treatment or refill, and which symptoms should bypass messaging for urgent or emergency assessment?

FAQs

Short answers for patients

Does Mounjaro cause constipation?

Constipation is a recognized common adverse reaction in current Mounjaro labeling. A label association does not prove Mounjaro caused one person’s bowel change, so timing, severity, intake, other medicines, medical history, and warning signs still need review.

How common is constipation with Mounjaro?

In pooled placebo-controlled trials in adults with type 2 diabetes, constipation occurred in 6%, 6%, and 7% across the three listed Mounjaro groups versus 1% with placebo. Keep those percentages tied to the adult trial table rather than combining them into one universal rate.

How long does Mounjaro constipation last?

The current label does not provide one expected duration. Record onset, duration, severity, exact presentation, bowel pattern, food and fluid intake, other symptoms, refill or treatment-change timing, and other medicines. Contact the prescriber for persistent, painful, recurrent, worsening, or function-limiting symptoms.

Can I take a laxative with Mounjaro?

Ask the responsible clinician or pharmacist before adding or combining laxatives. Severe pain, vomiting, inability to pass gas, marked swelling, bleeding, kidney or heart disease, pregnancy, fluid restrictions, other medicines, and the possible cause can change which options are appropriate or whether examination is needed first.

Should I skip Mounjaro if I am constipated?

Do not skip, repeat, stop, restart, split, or change Mounjaro based on generic online advice. Contact the responsible prescriber with the bowel pattern, other symptoms, intake, medicines, glucose context, and product details before the next treatment decision. Urgent warning signs require in-person assessment.

Do Mounjaro constipation rates apply to children or compounded tirzepatide?

Not automatically. The displayed constipation percentages come from adult placebo-controlled Mounjaro trials, so they do not establish a pediatric rate. A patient-specific compounded preparation is not FDA-approved Mounjaro and may differ in concentration, ingredients, presentation, labeling, storage, and beyond-use date.

When is constipation during Mounjaro care urgent?

Seek prompt in-person care for severe or persistent abdominal pain, repeated vomiting, marked abdominal swelling or rigidity, inability to pass stool or gas, blood or black stool, fainting, confusion, severe weakness, markedly reduced urination, or inability to keep fluids down.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current Eli Lilly MOUNJARO prescribing information — effective April 22, 2026 DailyMed API: Manufacturer MOUNJARO structured product label MedlinePlus: Tirzepatide injection drug information — revised February 15, 2026 MedlinePlus: Constipation FDA: Compounding and the FDA — Questions and Answers Peptide12: Mounjaro Peptide12: Mounjaro injection side effects Peptide12: Mounjaro and dehydration Peptide12: Tirzepatide constipation Peptide12: GLP-1 constipation Peptide12: Constipation medicines and peptide care Peptide12: Mounjaro missed dose Peptide12: When to message your clinician Peptide12: How online peptide therapy works